---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-24-000002"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:41:50.064941+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# VolitionRx receives $13.0M milestone from Heska for Nu.Q Vet Cancer Test transfer

## Summary
- Received $13.0 million in milestone payments from Heska Corporation.
- Milestone triggered by successful assay transfer of Nu.Q Vet Cancer Test onto Heska's Element i+ point-of-care platform.
- Payment stems from March 2022 License and Supply Agreement between Belgian Volition SRL and Heska.
- Test is marketed as the 'Heska Nu.Q Vet Canine Cancer Screen and Monitor.'

## SEC filing metadata
- accession: 0001477932-24-000002
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793224000002/0001477932-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793224000002/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-24-000002
- JSON: https://secwatch.observer/filing/0001477932-24-000002.json
- Plain text: https://secwatch.observer/filing/0001477932-24-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.